Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.08.2017 | original article

Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis

verfasst von: Xiuying Li, Jinfan Sun, Shuenqin Hu

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2017

Einloggen, um Zugang zu erhalten

Summary

Background

It has been shown that caveolin-1 plays a potential role as a diagnostic and prognostic biomarker in various cancer types. The aim of the present study was to clarify whether caveolin-1 expressed in the breast cancer stroma could be a prognostic factor for breast cancer patients.

Methods

We searched the PubMed, ScienceDirect and Web of Science databases for published literature investigating associations between stromal caveolin-1 expression and survival outcome in breast cancer patients. With respect to survival outcomes, the pooled hazard ratios (HRs) of caveolin-1 and the 95% confidence intervals (CI) were calculated.

Results

Our meta-analysis identified a total of 10 studies involving 2072 cases. Further investigation demonstrated that a lack of caveolin-1 expression in the breast cancer stroma is a hazard for overall survival (OS) (HR = 2.33, 95% CI: 1.57–3.46) and disease-free/progression-free survival (DFS/PFS) (HR = 3.05, 95% CI: 2.26–4.12) in breast cancer patients. Moreover, lack of caveolin-1 expression in the cancer-associated fibroblasts was a significant predictor of DFS/PFS (HR = 2.79, 95% CI: 1.75–4.46).

Conclusion

Our results indicated that lack of expression of caveolin-1 in the breast cancer stroma is associated with a poor prognosis.
Vorheriger Artikel Clinical and serological autoimmune complications in chronic lymphocytic leukemia
Nächster Artikel Assessment of individual cognitive changes after deep brain stimulation surgery in Parkinson’s disease using the Neuropsychological Test Battery Vienna short version
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.CrossRefPubMed
2.
3.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–36.PubMedPubMedCentral
4.
Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–49.CrossRefPubMed
5.
Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.CrossRefPubMed
6.
Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.CrossRefPubMed
7.
Martinez-Outschoorn U, Sotdia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol. 2014;41:195–216.CrossRefPubMed
8.
Pucci M, Bravata V, Forte GI, Cammarata FP, Messa C, Gilardi MC, Minafra L. Caveolin-1, breast cancer and ionizing radiation. Cancer Genomics Proteomics. 2015;12:143–52.PubMed
9.
Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther. 2010;10:135–43.CrossRefPubMedPubMedCentral
10.
Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 2012;227:490–8.CrossRefPubMed
11.
Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009;8:2420–4.CrossRefPubMedPubMedCentral
12.
Jia Y, Wang N, Wang J, Tian H, Ma W, Wang K, et al. Down-regulation of stromal caveolin-1 expression in esophageal squamous cell carcinoma: a potent predictor of lymph node metastases, early tumor recurrence, and poor prognosis. Ann Surg Oncol. 2014;21:329–36.CrossRefPubMed
13.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed
14.
Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(e51):3337–51.CrossRefPubMed
15.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data intometa-analysis. Trials. 2007;8:16.CrossRefPubMedPubMedCentral
16.
17.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed
18.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed
19.
20.
Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Bio Ther. 2009;8:1071–9.CrossRef
21.
El-Gendi SM, Mostafa MF, El-Gendi AM. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res. 2012;18:459–69.CrossRefPubMed
22.
Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174:2023–34.CrossRefPubMedPubMedCentral
23.
Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 2009;174:2035–43.CrossRefPubMedPubMedCentral
24.
Koo JS, Park S, Kim SI, Lee S, Park BW. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol. 2011;32:787–99.CrossRefPubMed
25.
Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandra R, et al. Using the “reverse Warburg effect” to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012;11:1108–17.CrossRefPubMedPubMedCentral
26.
Ren M, Liu F, Zhu Y, Li Y, Lang R, Fan Y, et al. Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome. Vichows Arch. 2014;465:291–8.CrossRef
27.
Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 2012;227:290–8.CrossRef
28.
Shan-Wei W, Kan-Lun X, Shu-Qin R, Li-Li Z, Li-Rong C. Overexpression of caveolin-1 in cancer-associated fibroblasts predicts good outcome in breast cancer. Breast Care (Basel). 2012;7:477–83.CrossRef
29.
Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, et al. Prognostic significance of tumor⁄stromal caveolin-1 expression in breast cancer patients. Cancer Sci. 2011;102:1590–6.CrossRefPubMed
30.
Ma X, Lei L, Nie W, Li Y, Zhang B, Zhang J, et al. Prognostic role of caveolin in breast cancer: a meta-analysis. Breast. 2013;22:462–9.CrossRefPubMed
31.
Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013;231:77–87.CrossRefPubMedPubMedCentral
32.
Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 2010;9:2423–33.CrossRefPubMed
33.
Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6(e92):375.CrossRefPubMed
Metadaten
Titel
Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis
verfasst von
Xiuying Li
Jinfan Sun
Shuenqin Hu
Publikationsdatum
01.08.2017
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2017
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1173-3

Weitere Artikel der Ausgabe 15-16/2017

Cystic fibrosis in Austria

  • original article

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna

  • Open Access
  • original article

Neurotoxicity of cyclosporine A in children with steroid-resistant nephrotic syndrome: is cytotoxic edema really an unfavorable predictor of permanent neurological damage?

  • short report

Clinical and serological autoimmune complications in chronic lymphocytic leukemia

  • original article

Clinical aspects of hantavirus infections in Bulgaria

  • original article

Erratum to: Assessment of individual cognitive changes after deep brain stimulation surgery in Parkinson’s disease using the Neuropsychological Test Battery Vienna short version

  • Erratum